What are the potential adverse effects of tacrolimus (immunosuppressive medication) in pediatric patients and how can they be managed?

Tacrolimus Adverse Effects in Pediatric Patients

Topical Tacrolimus (Ointment)

The most common adverse effects of topical tacrolimus in pediatric patients are localized skin burning and pruritus at the application site, which are typically mild, transient, and resolve within days of continued use. 1, 2

Common Local Adverse Effects

• Skin burning and stinging occur most frequently, particularly during the first few days of application, but generally diminish with continued use and are mild to moderate in severity 1, 2
• Pruritus (itching) at application sites is common but typically transient 2
• These local reactions are similar in frequency to vehicle/placebo in clinical trials 1

Infection Risk

• Cutaneous infections occur at similar rates to vehicle-treated patients in short-term trials 1, 2
• In pediatric atopic dermatitis trials, children aged 0-6 years treated with topical tacrolimus had higher rates of upper respiratory tract infections compared to placebo 1
• No increased risk of serious infections has been documented in large-scale studies 1

Systemic Absorption and Safety

• Systemic absorption is minimal in pediatric patients, with most having blood tacrolimus concentrations below the limit of quantification 2
• In children younger than 2 years, all patients maintained blood levels less than 1.5 ng/mL, well below levels associated with systemic toxicity 3
• No cases of lymphoma were reported in analysis of 5,825 pediatric patients across 21 long-term clinical trials (≥12 weeks duration) 1
• There is no evidence of systemic immunosuppression as measured by response to childhood immunizations and delayed hypersensitivity testing 1

Long-Term Safety Profile

• Topical tacrolimus has been used safely for up to 2 years in pediatric patients with atopic dermatitis 2
• The FDA boxed warning regarding potential cancer risk is not supported by clinical evidence in pediatric populations using topical formulations 1
• Analysis of malignancy rates shows no increased incidence of lymphoma compared to general population rates despite use in nearly 7 million persons 1

---

Systemic Tacrolimus (Oral/IV)

Systemic tacrolimus in pediatric transplant and immunosuppressive therapy carries significant risks of nephrotoxicity, neurotoxicity, hypertension, and new-onset diabetes, requiring close monitoring of drug levels and organ function. 4, 5, 6, 7

Nephrotoxicity (Kidney Damage)

• Nephrotoxicity occurs due to vasoconstriction of renal vasculature and direct tubular toxicity 4
• Manifests as elevated serum creatinine, hyperkalemia, decreased urea secretion, and hyperuricemia 4
• Usually reversible with dose reduction or temporary discontinuation when tacrolimus trough levels exceed recommended range 4
• Risk increases when combined with other nephrotoxic drugs (aminoglycosides, ganciclovir, amphotericin B) 4

Neurotoxicity and Neuropsychological Effects

• Tremor is the most common neurologic adverse effect, occurring in 44% of pediatric patients with inflammatory bowel disease 7
• Neuropsychological and behavioral symptoms occurred in 75% of one pediatric renal transplant cohort, including depression, anorexia-like symptoms with weight loss, amenorrhea, school problems, severe insomnia, and aggressive/anxious behavior 6
• These neuropsychological effects are fully reversible after discontinuation of tacrolimus 6
• Severe neurotoxicities include posterior reversible encephalopathy syndrome (PRES), delirium, seizures, and coma 4
• Seizures have been reported but are rare (occurred in 1 patient in one series) 6, 7
• Symptoms often correlate with tacrolimus trough levels at or above recommended range 4

Cardiovascular Effects

• Hypertension is common, occurring in 52% of pediatric patients with inflammatory bowel disease 7
• May require antihypertensive therapy, though avoid potassium-sparing agents due to hyperkalemia risk 4
• QT prolongation and risk of Torsades de pointes can occur; avoid in patients with congenital long QT syndrome 4

Metabolic Complications

• New-onset diabetes mellitus occurs in pediatric transplant patients, with African-American and Hispanic patients at increased risk 4
• May be reversible in some patients 4
• Hyperkalemia is common and requires monitoring of serum potassium levels 4
• Avoid concurrent use of potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers 4

Hematologic Effects

• Anemia has been reported 5
• Elevated platelet counts occurred in 4 of 12 patients in one pediatric series 3

Serious but Rare Complications

• Sepsis has been reported in pediatric patients 5
• Anaphylactic reactions can occur with IV formulation (0.6% incidence), likely related to castor oil derivatives 4

Drug Interactions and Monitoring Requirements

• CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) cause rapid, sharp rises in tacrolimus levels requiring dose reduction and frequent monitoring 4
• CYP3A4 inducers (rifampin, rifabutin) decrease tacrolimus levels 4
• Calcium-channel blockers increase tacrolimus blood concentrations 4
• Monitor tacrolimus whole blood trough concentrations regularly to maintain therapeutic range and avoid toxicity 1
• The therapeutic window is narrow: toxicity occurs at >15 μg/L (45% incidence) and rejection at <5 μg/L (30% incidence) 1

Management of Adverse Effects

• For nephrotoxicity: reduce dose or temporarily interrupt tacrolimus when serum creatinine is elevated and trough levels exceed recommended range 4
• For neurotoxicity: consider dose reduction or discontinuation 4
• For neuropsychological effects: discontinuation results in full reversal of symptoms 6
• Monitor blood glucose, serum creatinine, potassium, blood pressure, and tacrolimus trough levels throughout therapy 4

Critical Contraindications

• Do not combine with sirolimus in liver transplant patients (associated with excess mortality, graft loss, hepatic artery thrombosis) or heart transplant patients (increased renal impairment, wound complications, diabetes) 4